DK1192131T3 - Fremgangsmåde til inhibering af amyloid protein aggregering og afbildning af amyloidaflejringer under anvendelse af isoindolinderivater - Google Patents

Fremgangsmåde til inhibering af amyloid protein aggregering og afbildning af amyloidaflejringer under anvendelse af isoindolinderivater

Info

Publication number: DK1192131T3
Authority: DK; Denmark
Prior art keywords: imaging; amyloid; protein aggregation; inhibiting; isoindoline derivatives
Prior art date: 1999-06-10

Application number

DK00938023T

Other languages

Danish (da)

English (en)

Inventor

Corinne Elizab Augelli-Szafran

Yingjie Lai

Annette Theresa Sakkab

Lary Craswell Walker

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-10

Filing date

2000-05-31

Publication date

2004-12-13

2000-05-31 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2004-12-13 Application granted granted Critical

2004-12-13 Publication of DK1192131T3 publication Critical patent/DK1192131T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Optics & Photonics (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Radiology & Medical Imaging (AREA)
Neurology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK00938023T 1999-06-10 2000-05-31 Fremgangsmåde til inhibering af amyloid protein aggregering og afbildning af amyloidaflejringer under anvendelse af isoindolinderivater DK1192131T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US13854399P	1999-06-10	1999-06-10
EP00938023A EP1192131B1 (en)	1999-06-10	2000-05-31	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives
PCT/US2000/015073 WO2000076969A1 (en)	1999-06-10	2000-05-31	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number	Publication Date
DK1192131T3 true DK1192131T3 (da)	2004-12-13

Family

ID=22482508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK00938023T DK1192131T3 (da)	1999-06-10	2000-05-31	Fremgangsmåde til inhibering af amyloid protein aggregering og afbildning af amyloidaflejringer under anvendelse af isoindolinderivater

Country Status (38)

Country	Link
EP (1)	EP1192131B1 (cs)
JP (1)	JP2003502313A (cs)
KR (1)	KR20020012266A (cs)
CN (1)	CN1156445C (cs)
AP (1)	AP1398A (cs)
AT (1)	ATE272623T1 (cs)
AU (1)	AU777747B2 (cs)
BG (1)	BG106291A (cs)
BR (1)	BR0011446A (cs)
CA (1)	CA2373394A1 (cs)
CR (1)	CR6530A (cs)
CZ (1)	CZ20014366A3 (cs)
DE (1)	DE60012742T2 (cs)
DK (1)	DK1192131T3 (cs)
DZ (1)	DZ3262A1 (cs)
EA (1)	EA004405B1 (cs)
EE (1)	EE200100666A (cs)
ES (1)	ES2223531T3 (cs)
GE (1)	GEP20043407B (cs)
HK (1)	HK1046283B (cs)
HR (1)	HRP20020027A2 (cs)
HU (1)	HUP0201586A2 (cs)
IL (1)	IL146455A0 (cs)
IS (1)	IS6162A (cs)
MA (1)	MA26807A1 (cs)
MX (1)	MXPA01011112A (cs)
NO (1)	NO20015992L (cs)
NZ (1)	NZ515619A (cs)
OA (1)	OA11958A (cs)
PL (1)	PL352294A1 (cs)
PT (1)	PT1192131E (cs)
SI (1)	SI1192131T1 (cs)
SK (1)	SK17622001A3 (cs)
TR (1)	TR200200257T2 (cs)
UA (1)	UA64842C2 (cs)
WO (1)	WO2000076969A1 (cs)
YU (1)	YU86801A (cs)
ZA (1)	ZA200109164B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6972287B1 (en)	1999-06-10	2005-12-06	Pfizer Inc.	Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
AP2002002387A0 (en) *	1999-06-10	2002-03-31	Warner Lambert Co	Method of inhibiting amyloid aggregation and imaging amyloid deposits.
PE20020394A1 (es)	2000-08-18	2002-06-21	Agouron Pharma	Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) *	2000-09-29	2002-03-29	Warner-Lambert Company	Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) *	2000-12-21	2001-01-31	Glaxo Group Ltd	Napthalene derivatives
AR042206A1 (es) *	2002-11-26	2005-06-15	Novartis Ag	Acidos fenilaceticos y derivados
GB2404855A (en) *	2003-07-07	2005-02-16	Pantherix Ltd	Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es)	2006-06-26	2008-09-10	Novartis Ag	Derivados de acido fenilacetico
BRPI0719379A2 (pt) *	2006-11-24	2014-02-11	Ac Immune Sa	Composto, composição farmacêutica, uso de composto, mistura, métodos para coletar dados para o diagnóstico de uma doença ou condição associada com amilóide em uma amostra ou um paciente, para determinar a extensão da carga de placa amiloidogênica em um tecido e/ou um fluido corporal, para coletar dados para determinar a predisposição a uma doença ou condição associada com amilóide em um paciente, para coletar dados para monitorar a doença residual mínima em um paciente seguindo o tratamento com um anticorpo ou uma composição de vacina e para coletar dados para predizer a responsividade de um paciente sendo tratado com um anticorpo ou uma composição de vacina, e, kit de teste
EP2121633A2 (en)	2007-02-12	2009-11-25	Merck & Co., Inc.	Piperazine derivatives for treatment of ad and related conditions
WO2010000372A2 (en) *	2008-06-09	2010-01-07	Ludwig-Maximilians-Universität München	New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
CN102325765B (zh)	2009-02-06	2014-12-24	杨森制药公司	作为γ-分泌酶调节剂的取代的双环杂环化合物
TWI461425B (zh)	2009-02-19	2014-11-21	Janssen Pharmaceuticals Inc	作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CA2755467A1 (en) *	2009-05-07	2010-12-23	Janssen Pharmaceuticals, Inc.	Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
BR112012000915A2 (pt)	2009-07-15	2019-09-24	Janssen Pharmaceuticals Inc	derivados de triazol e imidazol substituídos como moduladores de gama secretase.
AU2011206635B2 (en)	2010-01-15	2015-01-22	Cellzome Limited	Novel substituted triazole derivatives as gamma secretase modulators
AU2012230348A1 (en)	2011-03-24	2013-08-29	Cellzome Limited	Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
ES2555167T3 (es)	2011-07-15	2015-12-29	Janssen Pharmaceuticals, Inc.	Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
CN104583208B (zh)	2012-05-16	2016-09-28	杨森制药公司	可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
AU2013366668B2 (en)	2012-12-20	2017-07-20	Janssen Pharmaceutica Nv	Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en)	2013-01-17	2017-06-22	Janssen Pharmaceutica Nv	Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en)	2014-01-16	2020-02-18	Janssen Pharmaceutica Nv	Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
MX368504B (es) *	2014-04-14	2019-10-04	Shanghai hengrui pharmaceutical co ltd	Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
US11071793B2 (en) *	2014-08-29	2021-07-27	Chdi Foundation, Inc.	Probes for imaging huntingtin protein
RS60906B1 (sr)	2014-10-06	2020-11-30	Vertex Pharma	Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
ES2946970T3 (es)	2016-03-31	2023-07-28	Vertex Pharma	Regulador de conductancia transmembrana de moduladores de fibrosis quística
LT3519401T (lt)	2016-09-30	2021-11-25	Vertex Pharmaceuticals Incorporated	Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
PT3551622T (pt)	2016-12-09	2020-11-12	Vertex Pharma	Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
WO2018140186A1 (en) *	2017-01-28	2018-08-02	Kingchem Life Science Llc	A process for preparing 5-phenoxy-1(3h)isobenzofuranone
US11253509B2 (en)	2017-06-08	2022-02-22	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
WO2019018395A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	METHODS OF TREATING CYSTIC FIBROSIS
TWI799435B (zh)	2017-08-02	2023-04-21	美商維泰克斯製藥公司	製備化合物之製程
CN109232533A (zh) *	2017-09-28	2019-01-18	北京越之康泰生物医药科技有限公司	氮杂环类衍生物、其制备方法及其医药用途
US10654829B2 (en)	2017-10-19	2020-05-19	Vertex Pharmaceuticals Incorporated	Crystalline forms and compositions of CFTR modulators
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en)	2018-04-13	2022-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MX2024000313A (es)	2021-07-09	2024-03-06	Plexium Inc	Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552426A (en) *	1994-04-29	1996-09-03	Eli Lilly And Company	Methods for treating a physiological disorder associated with β-amyloid peptide

2000
- 2000-05-31 YU YU86801A patent/YU86801A/sh unknown
- 2000-05-31 SI SI200030475T patent/SI1192131T1/xx unknown
- 2000-05-31 AT AT00938023T patent/ATE272623T1/de not_active IP Right Cessation
- 2000-05-31 PL PL00352294A patent/PL352294A1/xx not_active Application Discontinuation
- 2000-05-31 MX MXPA01011112A patent/MXPA01011112A/es not_active Application Discontinuation
- 2000-05-31 ES ES00938023T patent/ES2223531T3/es not_active Expired - Lifetime
- 2000-05-31 CZ CZ20014366A patent/CZ20014366A3/cs unknown
- 2000-05-31 AU AU53120/00A patent/AU777747B2/en not_active Ceased
- 2000-05-31 PT PT00938023T patent/PT1192131E/pt unknown
- 2000-05-31 HR HR20020027A patent/HRP20020027A2/hr not_active Application Discontinuation
- 2000-05-31 DE DE2000612742 patent/DE60012742T2/de not_active Expired - Fee Related
- 2000-05-31 IL IL14645500A patent/IL146455A0/xx unknown
- 2000-05-31 TR TR2002/00257T patent/TR200200257T2/xx unknown
- 2000-05-31 HU HU0201586A patent/HUP0201586A2/hu unknown
- 2000-05-31 JP JP2001503829A patent/JP2003502313A/ja active Pending
- 2000-05-31 EE EEP200100666A patent/EE200100666A/xx unknown
- 2000-05-31 NZ NZ515619A patent/NZ515619A/en unknown
- 2000-05-31 GE GE4625A patent/GEP20043407B/en unknown
- 2000-05-31 CA CA002373394A patent/CA2373394A1/en not_active Abandoned
- 2000-05-31 CN CNB008087288A patent/CN1156445C/zh not_active Expired - Fee Related
- 2000-05-31 EP EP00938023A patent/EP1192131B1/en not_active Expired - Lifetime
- 2000-05-31 OA OA1200100320A patent/OA11958A/en unknown
- 2000-05-31 AP APAP/P/2002/002389A patent/AP1398A/en active
- 2000-05-31 BR BR0011446-4A patent/BR0011446A/pt not_active IP Right Cessation
- 2000-05-31 KR KR1020017015827A patent/KR20020012266A/ko not_active Withdrawn
- 2000-05-31 DZ DZ003262A patent/DZ3262A1/fr active
- 2000-05-31 DK DK00938023T patent/DK1192131T3/da active
- 2000-05-31 WO PCT/US2000/015073 patent/WO2000076969A1/en not_active Ceased
- 2000-05-31 UA UA2001117664A patent/UA64842C2/uk unknown
- 2000-05-31 HK HK02107877.1A patent/HK1046283B/zh not_active IP Right Cessation
- 2000-05-31 EA EA200101133A patent/EA004405B1/ru not_active IP Right Cessation
- 2000-05-31 SK SK1762-2001A patent/SK17622001A3/sk unknown
2001
- 2001-11-06 ZA ZA200109164A patent/ZA200109164B/en unknown
- 2001-11-15 IS IS6162A patent/IS6162A/is unknown
- 2001-12-07 CR CR6530A patent/CR6530A/es not_active Application Discontinuation
- 2001-12-07 NO NO20015992A patent/NO20015992L/no not_active Application Discontinuation
2002
- 2002-01-03 MA MA26467A patent/MA26807A1/fr unknown
- 2002-01-09 BG BG106291A patent/BG106291A/bg unknown

Also Published As

Publication number	Publication date
EP1192131A1 (en)	2002-04-03
WO2000076969A1 (en)	2000-12-21
ES2223531T3 (es)	2005-03-01
CN1355790A (zh)	2002-06-26
YU86801A (sh)	2004-07-15
PL352294A1 (en)	2003-08-11
CR6530A (es)	2004-03-24
ZA200109164B (en)	2003-02-06
MA26807A1 (fr)	2004-12-20
PT1192131E (pt)	2004-11-30
EA004405B1 (ru)	2004-04-29
CA2373394A1 (en)	2000-12-21
NO20015992D0 (no)	2001-12-07
JP2003502313A (ja)	2003-01-21
NZ515619A (en)	2003-05-30
CN1156445C (zh)	2004-07-07
DE60012742T2 (de)	2005-01-13
IS6162A (is)	2001-11-15
CZ20014366A3 (cs)	2002-11-13
AU777747B2 (en)	2004-10-28
HK1046283B (zh)	2005-01-07
MXPA01011112A (es)	2002-06-04
BR0011446A (pt)	2002-03-19
OA11958A (en)	2006-04-13
AU5312000A (en)	2001-01-02
SI1192131T1 (en)	2004-12-31
DZ3262A1 (fr)	2000-12-12
HUP0201586A2 (en)	2002-08-28
NO20015992L (no)	2002-02-06
HRP20020027A2 (en)	2005-02-28
AP1398A (en)	2005-04-21
UA64842C2 (uk)	2004-03-15
EE200100666A (et)	2003-02-17
EP1192131B1 (en)	2004-08-04
ATE272623T1 (de)	2004-08-15
IL146455A0 (en)	2002-07-25
AP2002002389A0 (en)	2002-03-31
SK17622001A3 (sk)	2003-06-03
GEP20043407B (en)	2004-05-10
EA200101133A1 (ru)	2002-06-27
TR200200257T2 (tr)	2002-06-21
DE60012742D1 (de)	2004-09-09
BG106291A (bg)	2002-05-31
HK1046283A1 (en)	2003-01-03
KR20020012266A (ko)	2002-02-15

Publication	Publication Date	Title
NO20015992L (no)	2002-02-06	Fremgangsmåte for inhibering av amyloidprotein-aggregering og billeddannelse av amyloidavleiring ved bruk av isoindolin-derivater
EA200000274A3 (ru)	2003-02-27	Способы получения и промежуточные соединения для получения противораковых соединений
EE200200183A (et)	2003-06-16	Meetod polüisobuteenfenooli sisaldavate Mannichi aduktide saamiseks
ATE293610T1 (de)	2005-05-15	2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
NO20020635D0 (no)	2002-02-08	Proteinpolymeriseringsinhibitorer og fremgangsmåter for anvendelse
DK0971735T3 (da)	2008-07-07	Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
DK1218348T3 (da)	2008-02-25	Indazolforbindelser og farmaceutiske sammensætninger til inhibering af proteinkinaser og fremgangsmåder til deres anvendelse
NO20004741L (no)	2000-11-22	Farmasöytiske blandinger for forlenget peptidfrigjöring og fremstillingsmetode
ATE275145T1 (de)	2004-09-15	Chinazolinderivate zur behandlung von tumoren
NO20015859L (no)	2002-02-01	A-<beta>-peptidpreparater og fremgangsmåte for fremstilling av slike
ATE269303T1 (de)	2004-07-15	Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
NO20021412L (no)	2002-04-17	Soyamelkeblandinger og fremgangsmåter for fremstilling
NO20021736D0 (no)	2002-04-12	Nytt preparat og fremgangsmåte for stabilisering av det
NO20004896D0 (no)	2000-09-29	Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav
NO20015995L (no)	2002-02-04	Metode for inhibering av amyloid-protein-aggregering og billeddannelse av amyloid-avleiringer
NO20013914L (no)	2001-10-10	Temperaturkompensert NMR-apparat og -fremgangsmåte
NO20003070D0 (no)	2000-06-15	Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
DK1147075T3 (da)	2003-12-08	Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DE60008820D1 (de)	2004-04-15	Bilderzeugungsverfahren und Bilderzeugungsgerät
EP1232159A4 (en)	2004-03-31	AMYLO DE-BETA PEPTIDE INHIBITORS
DK1031565T3 (da)	2002-11-11	Hidtil ukendte krystaller af depsipeptidderivat og fremgangsmåde til fremstilling heraf
EP1158983A4 (en)	2003-05-21	Prenyl protein transferase inhibitors
DK1044592T3 (da)	2004-10-25	Fremgangsmåde og apparat til gödskning af jord
NO20003881D0 (no)	2000-07-28	Bibapcitid-baserte farmasøytiske sammensetninger for avbildning og behandling av thromber
SI1080076T1 (sl)	2004-04-30	Izboljšan postopek za pripravo farmacevtsko pomembnih norbenzomorfanskih derivatov